Published in Hospital Law Weekly, May 27th, 2004
The researchers are using new research and technology that shows bone-marrow-derived mesenchymal stem cells (MSCs) will engraft at the site of a tumor and contribute to the growth of stromal fibroblasts (the healthy tissue surrounding a tumor. The procedure proved to be over a thousand times more efficient than other vector systems. The research, the first of its kind, was presented at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.